Physician profile
Lynn Luthern
NPI 1003204231
$2,786.93
in general payments reported to CMS, 2019-2025
24 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,454 · 2022: $853 · 2023: $84.49 · 2024: $108 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $385.44 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $316.31 | 2021-2022 | |
| Merz North America, INC. | $312.26 | 2024-2025 | |
| Abbvie INC. | $248.48 | 2022-2025 | |
| Corcept Therapeutics | $241.46 | 2021-2022 | |
| Lilly USA, LLC | $209.02 | 2021-2022 | |
| Edwards Lifesciences Corporation | $163.82 | 2022 | |
| Amgen INC. | $131.34 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $101.77 | 2021-2022 | |
| Abbott Laboratories | $83.43 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $77.09 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $73.57 | 2021-2022 | |
| Mannkind Corporation | $72.57 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $63.85 | 2021-2022 | |
| Radius Health, INC. | $60.51 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $46.43 | 2021 | |
| Eusa Pharma (US) LLC | $38.48 | 2022 | |
| Xeris Pharmaceuticals, INC. | $30.20 | 2022 | |
| Ibsa Pharma INC. | $27.99 | 2021 | |
| Pinnacle, INC | $26.08 | 2023 | |
| Medtronic, INC. | $23.76 | 2021 | |
| Tandem Diabetes Care, INC. | $23.28 | 2021 | |
| Amarin Pharma, INC. | $16.23 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Luthern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.